| Citation: |
Cervical Cancer Prevention and Control Research Professional Committee of Chinese Association for Maternal and Child Health Study. Chinese Expert Consensus on Application of HPV Vaccine in Perioperative Treatment of High-Grade Cervical Intraepithelial Neoplasia (2025 Edition)[J]. Cancer Research on Prevention and Treatment, 2025, 52(3): 177-184. DOI: 10.3971/j.issn.1000-8578.2025.25.0012
|
In women with high-grade squamous intraepithelial lesion (HSIL) undergoing excision therapy, vaccination with human papillomavirus (HPV) vaccine may reduce the risk of postoperative recurrence. However, research data and clear application guidelines are currently limited in China. The Cervical Cancer Prevention and Control Research Committee of the China Maternal and Child Health Research Association gathered a team of relevant experts to develop the consensus based on the characteristics of clinical practice in China. This expert consensus suggests that women of appropriate age, without contraindications, with histopathological confirmation of HSIL, and who underwent excision treatment should receive a prophylactic HPV vaccine to reduce the risk of recurrence. The recommended vaccination time is as early as possible after HSIL diagnosis or after resection treatment, and the recommended vaccination procedure is three doses. For women who have already received an HPV vaccine before treatment, there is no need to receive again after excision therapy. For women who underwent resection treatment, even if they have received HPV vaccines, regular follow-up should still be conducted in accordance with the post-treatment management guidelines. Vaccination cannot replace routine follow-up.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancersin185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10.3322/caac.21834
|
| [2] |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. doi: 10.1016/j.jncc.2024.01.006
|
| [3] |
Yang M, Du J, Lu H, et al. Global trends and age-specific incidence and mortality of cervical cancer from1990 to 2019: an international comparative study based on the Global Burden of Disease[J]. BM J Open, 2022, 12(7): e055470. doi: 10.1136/bmjopen-2021-055470
|
| [4] |
Xia C, Hu S, Xu X, et al. Projections up to 2100 and a budget optimisation strategy towards cervical cancer elimination in China: a modelling study[J]. Lancet Public Health, 2019, 4(9): e462-e472. doi: 10.1016/S2468-2667(19)30162-8
|
| [5] |
陈号, 夏昌发, 由婷婷, 等. 中国女性宫颈癌负担快速上升的原因及其应对措施[J]. 中华流行病学杂志, 2022, 43(5): 761-765. [Chen H, Xia C, You T, et al. Causes and countermeasures of the rapidly rising burden on cervical cancer in Chinese women[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2022, 43(5): 761-765.] doi: 10.3760/cma.j.cn112338-20211004-00765
Chen H, Xia C, You T, et al. Causes and countermeasures of the rapidly rising burden on cervical cancer in Chinese women[J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2022, 43(5): 761-765. doi: 10.3760/cma.j.cn112338-20211004-00765
|
| [6] |
Sankaranarayanan R. HPV vaccination: The most pragmatic cervical cancer primary prevention strategy[J]. Int J Gynaecol Obstet, 2015, 131(Suppl 1): S33-S35.
|
| [7] |
赵超, 毕蕙, 赵昀, 等. 子宫颈高级别上皮内病变管理的中国专家共识[J]. 中国妇产科临床杂志, 2022, 23(2): 220-224. [Zhao C, Bi H, Zhao Y, et al. Chinese expert consensus on the Management of High-grade intraepithelial lesions[J]. Zhongguo Fu Chan Ke Lin Chuang Za Zhi, 2022, 23(2): 220-224.]
Zhao C, Bi H, Zhao Y, et al. Chinese expert consensus on the Management of High-grade intraepithelial lesions[J]. Zhongguo Fu Chan Ke Lin Chuang Za Zhi, 2022, 23(2): 220-224.
|
| [8] |
中国优生科学协会阴道镜和子宫颈病理学分会, 中华医学会妇科肿瘤学分会, 中国抗癌协会妇科肿瘤专业委员会, 等. 中国子宫颈癌筛查指南(一)[J]. 中国妇产科临床杂志, 2023, 24(4): 437-442. [Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association, Chinese Society of Gynecologic oncology, Chinese Medical Association, Chinese Gynecological Cancer Society, et al. Guidelines for cervical cancer screening in China (Part One)[J]. Zhongguo Fu Chan Ke Lin Chuang Za Zhi, 2023, 24(4): 437-442.]
Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association, Chinese Society of Gynecologic oncology, Chinese Medical Association, Chinese Gynecological Cancer Society, et al. Guidelines for cervical cancer screening in China (Part One)[J]. Zhongguo Fu Chan Ke Lin Chuang Za Zhi, 2023, 24(4): 437-442.
|
| [9] |
Arbyn M, Redman CWE, Verdoodt F. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis[J]. Lancet Oncol, 2017, 18(12): 1665-1679. doi: 10.1016/S1470-2045(17)30700-3
|
| [10] |
Reuschenbach M, Doorbar J, Del Pino M, et al. Prophylactic HPV vaccines in patients with HPV-associated diseases and cancer[J]. Vaccine, 2023, 41(42): 6194-6205. doi: 10.1016/j.vaccine.2023.08.047
|
| [11] |
Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia(CIN2-3)[J]. Gynecol Oncol, 2013, 130(2): 264-268. doi: 10.1016/j.ygyno.2013.04.050
|
| [12] |
Velentzis LS, Brotherton JML, Canfell K. Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a rolein prevention of secondary lesions[J]. Climacteric, 2019, 22(6): 596-602. doi: 10.1080/13697137.2019.1600500
|
| [13] |
Del Pino M, Martí C, Torras I, et al. HPV Vaccination as Adjuvant to Conization in Women with Cervical Intraepithelial Neoplasia: A Study under Real-Life Conditions[J]. Vaccines(Basel), 2020, 8(2): 245.
|
| [14] |
Arroyo Mühr LS, Lagheden C, Hassan SS, et al. The International Human Papillomavirus Reference Center: Standardization, collaboration, and quality assurance in HPV research and diagnostics[J]. J Med Virol, 2023, 95(12): e29332. doi: 10.1002/jmv.29332
|
| [15] |
Williamson AL. Recent Developments in Human Papillomavirus (HPV) Vaccinology[J]. Viruses, 2023, 15(7): 1440. doi: 10.3390/v15071440
|
| [16] |
Okunade KS. Human papillomavirus and cervical cancer[J]. J Obstet Gynaecol, 2020, 40(5): 602-608. doi: 10.1080/01443615.2019.1634030
|
| [17] |
World Health Organization. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations[J]. Vaccine, 2017, 35(43): 5753-5755. doi: 10.1016/j.vaccine.2017.05.069
|
| [18] |
World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention[EB/OL]. 2nd ed. [2021-07-06]. https://www.who.int/publications/i/item/9789240030824.
|
| [19] |
Wei F, Georges D, Man I, et al. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature[J]. Lancet, 2024, 404(10451): 435-444. doi: 10.1016/S0140-6736(24)01097-3
|
| [20] |
Loopik DL, Bentley HA, Eijgenraam MN, et al. The Natural History of Cervical Intraepithelial Neoplasia Grades1, 2, and 3: A Systematic Review and Meta-analysis[J]. J Low Genit Tract Dis, 2021, 25(3): 221-231. doi: 10.1097/LGT.0000000000000604
|
| [21] |
Hughes KC, Herring TA, Song JN, et al. Cervical High-Grade Squamous Intraepithelial Lesion Burden and Standard of Care Treatment Effectiveness and Safety in the United States, 2008-2018: The EACH-WOMAN Project[J]. J Low Genit Tract Dis, 2023, 27(2): 105-112. doi: 10.1097/LGT.0000000000000719
|
| [22] |
Lin S, Gao K, Gu S, et al. Worldwide trends in cervical cancer incidence and mortality, with predictions for the next 15 years[J]. Cancer, 2021, 127(21): 4030-4039. doi: 10.1002/cncr.33795
|
| [23] |
赵昀, 魏丽惠. CSCCP关于中国宫颈癌筛查及异常管理相关问题专家共识解读[J]. 实用妇产科杂志, 2018, 34(2): 101-104. [Zhao Y, Wei LH. CSCCP Interpretation on Chinese expert consensus on Cervical Cancer Screening and Abnormal Management[J]. Shi Yong Fu Chan Ke Za Zhi, 2018, 34(2): 101-104.]
Zhao Y, Wei LH. CSCCP Interpretation on Chinese expert consensus on Cervical Cancer Screening and Abnormal Management[J]. Shi Yong Fu Chan Ke Za Zhi, 2018, 34(2): 101-104.
|
| [24] |
王临虹, 赵更力. 子宫颈癌综合防控指南[M]. 第2版. 北京: 人民卫生出版社, 2023: 75-80. [Wang LH, Zhao GL. Guidelines forComprehensive Prevention and Control of Cervical Cancer [M]. 2nd ed. Beijing: People’s Medical Publishing House, 2023: 75-80.]
Wang LH, Zhao GL. Guidelines forComprehensive Prevention and Control of Cervical Cancer [M]. 2nd ed. Beijing: People’s Medical Publishing House, 2023: 75-80.
|
| [25] |
Jiang Y, Chen C, Li L. Comparison of Cold-Knife Conization versus Loop Electrosurgical Excision for Cervical Adenocarcinoma In Situ(ACIS): A Systematic Review and Meta-Analysis[J]. PLoS One, 2017, 12(1): e0170587. doi: 10.1371/journal.pone.0170587
|
| [26] |
Loopik DL, IntHout J, Ebisch RMF, et al. The risk of cervical cancer after cervical intraepithelial neoplasia grade 3: A population-based cohort study with 80, 442 women[J]. Gynecol Oncol, 2020, 157(1): 195-201. doi: 10.1016/j.ygyno.2020.01.023
|
| [27] |
Hoffman SR, Le T, Lockhart A, et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review[J]. Int J Cancer, 2017, 141(1): 8-23. doi: 10.1002/ijc.30623
|
| [28] |
Zhang Y, Ni Z, Wei T, et al. Persistent HPV infection after conization of cervical intraepithelial neoplasia-a systematic review and meta-analysis[J]. BMC Womens Health, 2023, 23(1): 216. doi: 10.1186/s12905-023-02360-w
|
| [29] |
Rositch AF, Soeters HM, Offutt-Powell TN, et al. The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review[J]. Gynecol Oncol, 2014, 132(3): 767-779. doi: 10.1016/j.ygyno.2013.12.040
|
| [30] |
Sand FL, Kjaer SK, Frederiksen K, et al. Risk of cervical intraepithelial neoplasia grade 2 or worse after conization in relation to HPV vaccination status[J]. Int J Cancer, 2020, 147(3): 641-647. doi: 10.1002/ijc.32752
|
| [31] |
Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors[J]. Cochrane Database Syst Rev, 2018, 5(5): CD009069.
|
| [32] |
Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis[J]. Lancet, 2019, 394(10197): 497-509. doi: 10.1016/S0140-6736(19)30298-3
|
| [33] |
Palmer T, Wallace L, Pollock K, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study[J]. BMJ, 2019, 365: l1161.
|
| [34] |
Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data[J]. BMJ, 2012, 344: e1401. doi: 10.1136/bmj.e1401
|
| [35] |
Garland SM, Paavonen J, Jaisamrarn U, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial[J]. Int J Cancer, 2016, 139(12): 2812-2826. doi: 10.1002/ijc.30391
|
| [36] |
Ghelardi A, Parazzini F, Martella F, et al. SPERANZA project: HPV vaccination after treatment for CIN2[J]. Gynecol Oncol, 2018, 151(2): 229-234. doi: 10.1016/j.ygyno.2018.08.033
|
| [37] |
Lichter K, Krause D, Xu J, et al. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis[J]. Obstet Gynecol, 2020, 135(5): 1070-1083. doi: 10.1097/AOG.0000000000003833
|
| [38] |
Casajuana-Pérez A, Ramírez-Mena M, Ruipérez-Pacheco E, et al. Effectiveness of Prophylactic Human Papillomavirus Vaccine in the Prevention of Recurrence in Women Conized for HSIL/CIN2-3: The VENUS Study[J]. Vaccines(Basel), 2022, 10(2): 288.
|
| [39] |
Bartels HC, Postle J, Rogers AC, et al. Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis[J]. Int J Gynecol Cancer, 2020, 30(6): 777-782. doi: 10.1136/ijgc-2020-001197
|
| [40] |
Di Donato V, Caruso G, Petrillo M, et al. Adjuvant HPV vaccination to prevent recurrent cervical dysplasia after surgical treatment: Ameta-analysis[J]. Vaccines(Basel), 2021, 9(5): 410.
|
| [41] |
Karimi-Zarchi M, Allahqoli L, Nehmati A, et al. Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agentin women with CIN? A randomized trial[J]. BMC Public Health, 2020, 20(1): 274. doi: 10.1186/s12889-020-8371-z
|
| [42] |
Dvořák V, Petráš M, Dvořák V, et al. Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: Retrospective cohort study[J]. Hum Vaccin Immunother, 2024, 20(1): 2343552. doi: 10.1080/21645515.2024.2343552
|
| [43] |
张梦培, 尹如铁. HPV疫苗对子宫颈癌前病变治疗后人群的保护[J]. 实用妇产科杂志, 2022, 38(11): 813-815. [Zhang MP, Yin RT. Protection of HPV vaccine after treatment of precancerous lesions of cervical cancer[J]. Shi Yong Fu Chan Ke Za Zhi, 2022, 38(11): 813-815.]
Zhang MP, Yin RT. Protection of HPV vaccine after treatment of precancerous lesions of cervical cancer[J]. Shi Yong Fu Chan Ke Za Zhi, 2022, 38(11): 813-815.
|
| [44] |
van de Laar RLO, Hofhuis W, Duijnhoven RG, et al. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial[J]. BMC Cancer, 2020, 20(1): 539. doi: 10.1186/s12885-020-07025-7
|
| [45] |
Martínez-Gómez X, Curran A, Campins M, et al. Multidisciplinary, evidence-based consensus guidelines for human papillomavirus (HPV) vaccination in high-risk populations, Spain, 2016[J]. Euro Surveill, 2019, 24(7): 1700857.
|
| [46] |
Joura EA, Kyrgiou M, Bosch FX, et al. Human papillomavirus vaccination: The ESGO-EFC position paper of the European society of Gynaecologic Oncology and the European Federation for colposcopy[J]. Eur J Cancer, 2019, 116: 21-26. doi: 10.1016/j.ejca.2019.04.032
|
| [47] |
中华医学会妇科肿瘤学分会, 中国优生科学协会阴道镜和宫颈病理学分会. 人乳头瘤病毒疫苗临床应用中国专家共识[J]. 中国医学前沿杂志(电子版), 2021, 13(2): 1-12. [Chinese Society of Gynecologic oncology, Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association. Chinese expert consensus on clinical application of human papillomavirus vaccine[J]. Zhongguo Yi Xue Qian Yan Za Zhi(Dian Zi Ban), 2021, 13(2): 1-12.]
Chinese Society of Gynecologic oncology, Chinese Medical Association, Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association. Chinese expert consensus on clinical application of human papillomavirus vaccine[J]. Zhongguo Yi Xue Qian Yan Za Zhi(Dian Zi Ban), 2021, 13(2): 1-12.
|
| [48] |
Sharpless KE, Marcus JZ, Kuroki LM, et al. ASCCP Committee Opinion: Adjuvant Human Papillomavirus Vaccine for Patients Undergoing Treatment for Cervical Intraepithelial Neoplasia[J]. J Low Genit Tract Dis, 2023, 27(1): 93-96. doi: 10.1097/LGT.0000000000000703
|
| [49] |
Mariz FC, Bender N, Anantharaman D, et al. Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines[J]. NPJ Vaccines, 2020, 5(1): 14. doi: 10.1038/s41541-020-0165-x
|
| [50] |
Athanasiou A, Bowden S, Paraskevaidi M, et al. HPV vaccination and cancer prevention[J]. Best Pract Res Clin Obstet Gynaecol, 2020, 65: 109-124. doi: 10.1016/j.bpobgyn.2020.02.009
|
| [51] |
Beyer WEP, Osterhaus ADME. Bivalent AS04-adjuvanted HPV vaccine provides optimal cancer prevention for HPV types not included in the vaccine[J]. Vaccine, 2020, 38(47): 7414-7416. doi: 10.1016/j.vaccine.2020.09.015
|
| [52] |
Berti FCB, Pereira APL, Cebinelli GCM, et al. The role of interleukin 10 in human papilloma virus infection and progression to cervical carcinoma[J]. Cytokine Growth Factor Rev, 2017, 34: 1-13. doi: 10.1016/j.cytogfr.2017.03.002
|
| [53] |
Gnanagurusamy J, Krishnamoorthy S, Muthusami S. Transforming growth factor-β micro-environment mediated immune cell functions in cervical cancer[J]. Int Immunopharmacol, 2024, 140: 112837. doi: 10.1016/j.intimp.2024.112837
|
| [54] |
Li J, Liu Y, Song J, et al. Analysis of Serum Levels of IFN-γ, IL-4, and TNF-α in Patients with Cervicitis Complicated by HPV Infection and Their Clinical Significance[J]. J Healthc Eng, 2022, 2022: 3374655.
|
| [55] |
Saftlas AF, Spracklen CN, Ryckman KK, et al. Infuence of a loop electrosurgical excision procedure (LEEP) on levels of cytokines in cervical secretions[J]. J Reprod Immunol, 2015, 109: 74-83. doi: 10.1016/j.jri.2015.01.002
|
| [56] |
Das CR, Tiwari D, Dongre A, et al. Deregulated TNF-Alpha Levels Along with HPV Genotype 16 Infection Are Associated with Pathogenesis of Cervical Neoplasia in Northeast Indian Patients[J]. Viral Immunol, 2018, 31(4): 282-291. doi: 10.1089/vim.2017.0151
|
| [57] |
Zurek MM, Toft L, KubeT, et al. Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection[J]. Hum Vaccines Immunother, 2018, 14(4): 909-916. doi: 10.1080/21645515.2017.1407896
|
| [58] |
Henere C, Torné A, Llupià A, et al. HPV vaccination in women with cervical intraepithelial neoplasia undergoing excisional treatment: insights into unsolved questions[J]. Vaccines (Basel), 2022, 10(6): 887. doi: 10.3390/vaccines10060887
|
| [59] |
Tjalma WAA, van Heerden J, Van den Wyngaert T. If prophylactic HPV vaccination is considered in a woman with CIN2+, what is the value and should it be given before or after the surgical treatment?[J]. Eur J Obstet Gynecol Reprod Biol, 2022, 269: 98-101. doi: 10.1016/j.ejogrb.2021.11.008
|
| [60] |
Petráš M, Dvořák V, Lomozová D, et al. Timing of HPV vaccination as adjuvant treatment of CIN2+ recurrence in women undergoing surgical excision: a meta-analysis and meta-regression[J]. Sex Transm Infect, 2023, 99(8): 561-570. doi: 10.1136/sextrans-2023-055793
|
| [61] |
Johnson Jones ML, Gargano JW, Powell M, et al. Effectiveness of 1, 2, and 3 Doses of Human Papillomavirus Vaccine Against High-Grade Cervical Lesions Positive for Human Papillomavirus 16 or 18[J]. Am J Epidemiol, 2020, 189(4): 265-276. doi: 10.1093/aje/kwz253
|
| [62] |
Kalliala I, Athanasiou A, Veroniki AA, et al. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta- analysis of the literature[J]. Ann Oncol, 2020, 31(2): 213-227. doi: 10.1016/j.annonc.2019.11.004
|
Tables(1)
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: